FDIC Reports Earnings Decline For Banks In Third

New Post Public Reply Private Reply Replies (0) Message Board
SaltyMutt

FDIC Reports Earnings Decline For Banks In Third Quarter

Bank The Quarterly Banking Profile released by the FDIC showed that profits for the banking industry declined for the first time since the second quarter of 2009.

FDIC insured commercial banks and savings institutions reported net income of $36.0 billion for the third quarter of 2013 which was a $1.5 billion (3.9%) decline from the previous year. The FDIC attributed the lower quarterly earnings to a $4 billion increase in legal expenses at “one institution.”

Although the FDIC did not name the bank involved it is no secret that the bank in question was JPMorgan Chase & Co. which reported a third quarter loss of $380 million after taking a $7.2 billion charge to cover litigation and regulatory investigations. JPMorgan has been under relentless assault by regulators ever since the financial crisis of 2008 and a trading loss of $6.2 billion in 2012. Since 2010 JPMorgan has set aside a massive $20 billion for legal and regulatory costs and spent $8 billion on legal fees.

Quarterly banking profits were also adversely impacted by lower mortgage fees as refinancing activity declined due to the increase in interest rates and from lower gains on asset sales.

Of the 6,891 institutions insured by the FDIC, half had an increase in earnings over the prior year and half saw earnings decline. Five years after the banking crisis 8.6% of all banks are still unprofitable although the number declined from 10.7% from the prior year. Another sign of weakness during the quarter was shown by the decline in return on assets to 0.99% from 1.06% a year ago and a decline on average return on equity to 8.92% from 9.35% a year ago.

Another sign of a banking industry still struggling to recover was shown by a decline of 3.6% or $6.1 billion in third quarter net operating revenue to $163.3 billion. Also contributing to a slow banking industry recovery is the low average net interest margin of 3.26% which is at the lowest level since reaching 3.2% in the fourth quarter of 2006. The average net interest margin in the difference between a bank’s average yield earned on loans and the average cost of funding loans and investments.

FDIC

Banks benefited in the third quarter from lower loan loss provisions of $5.8 billion which was down $8.8 billion or 60% from the previous year and the lowest since the third quarter of 1999. Noncurrent loans and leases 90 days or more past due declined by $18.3 billion or 7.7% from last year and delinquencies declined to 2.83%, the lowest level since the third quarter of 2008.

Total loan balances increased by $69.7 billion or 0.9% during the quarter but income from mortgage originations declined by 45% from the prior year as higher mortgage rates reduced the demand for mortgage refinances.

Summarizing the third quarter results, FDIC Chairman Martin J. Gruenberg noted that “Most of the positive trends we have been seeing in industry performance continued in the third quarter. Fewer institutions reported quarterly losses, lending grew at a modest pace, credit quality continued to improve, more banks came off the ‘Problem List,’ and fewer banks failed.”

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 249

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Tencent Cloud's Edge Platform Shines in New Gartner Report

Updated Category News Views 61

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 307

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Strathcona and Greenfire Set Sights on Major Merger

Updated Category News Views 138

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 203

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cars.com Inducement Awards: New CPO Earns Stock Boost

Updated Category News Views 76

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Continue Reading
AI Shopping Surge: WeFetch.ai's Bold Rebrand Move

Updated Category News Views 48

Shifting Gears: GreenCore Solutions Becomes WeFetch.ai Here's a shift you don't see every day. GreenCore Solutions has morphed into WeFetch.ai, aiming to sail the ever-growing AI shopping seas. This isn't just a new nameplate; it's a declaration of intent to dive headfirst into the market dynamics driven by artificial intelligence. It's bold and, frankly, pretty timely....

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 149

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Mako Hiraizumi Shines with Silver at Japan Triathlon

Updated Category News Views 41

A Triathlete with Grit and Ambition Mako Hiraizumi didn't just earn a silver medal at the 32nd Japan Triathlon National Championships; she set an example of perseverance and ambition. Rising a notch from her bronze finish last year, Hiraizumi's runner-up achievement at Tokyo's Odaiba Seaside Park is no small feat. Yet, she's not resting on her laurels. This athlete from...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 482

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading

Top 5 Most Recently Viewed Articles

Abeona Therapeutics' ZEVASKYN Receives FDA Approval, a New Hope

Updated Category News Views 147

A Revolutionary Breakthrough for Epidermolysis Bullosa In an incredible achievement for the EB community, Abeona Therapeutics has received FDA approval for ZEVASKYN, which is poised to change the landscape for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). This marks a historic moment as the third FDA-approved treatment for RDEB and the first autologous,...

Continue Reading
Zero Candida Reaches Major Milestone with ZC-001 Device Development

Updated Category News Views 127

Zero Candida Marks Milestone with ZC-001 Prototype Production Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) has achieved a remarkable milestone in its quest to revolutionize women's health. The company recently announced the commencement of prototype production for its groundbreaking therapeutic device, ZC-001, designed specifically for the treatment of...

Continue Reading
Bitcoin's Future and Market Dynamics: Insights from a Veteran Trader

Updated Category News Views 86

Cautious Optimism for Bitcoin and Other Cryptocurrencies Pseudonymous veteran trader DonAlt expresses a cautious outlook on leading cryptocurrencies like Bitcoin, Ethereum, and Dogecoin. His insights on market trends reveal an intriguing perspective for investors in these digital assets. Current Market Situation DonAlt has recently shared his thoughts on the performance...

Continue Reading
Alibaba Settles for $433.5 Million in Shareholder Lawsuit

Updated Category News Views 220

Alibaba Reaches Settlement in Lawsuit Alibaba (NYSE: BABA), China’s leading e-commerce powerhouse, has recently taken a significant step in addressing legal challenges by agreeing to pay $433.5 million to settle a class-action lawsuit in the United States. This lawsuit, brought forth by investors, accused Alibaba of engaging in monopolistic practices. The company's...

Continue Reading
Class Action Alert: Telix Pharmaceuticals Lawsuit Overview

Updated Category News Views 174

Understanding the Telix Pharmaceuticals Class Action In a significant development, investors of Telix Pharmaceuticals Limited are currently facing a class action lawsuit. This initiative, spearheaded by Bronstein, Gewirtz & Grossman LLC, invites those affected by substantial losses in their investments to take action. The law firm is renowned for its dedication in...

Continue Reading